GlassScriptPhysician profile
Narendir T Soorya
NPI 1922021955
$4,773.25
in general payments reported to CMS, 2019-2025
30 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $130 · 2021: $611 · 2022: $467 · 2023: $905 · 2024: $959 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,359 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.69 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.48 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $620.21 | 2020-2025 | Caplyta |
| Alkermes, INC. | $430.31 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $346.94 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $336.90 | 2019-2025 | Rexulti, Vyepti |
| Otsuka America Pharmaceutical, INC. | $284.25 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $187.40 | 2021-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $186.32 | 2022-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $167.71 | 2022-2024 | Austedo Xr, Austedo |
| Orexo US, INC. | $165.07 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.46 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $149.60 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $143.38 | 2019-2022 | |
| Axsome Therapeutics, INC. | $121.88 | 2023-2025 | Auvelity, Sunosi |
| Allergan, INC. | $102.49 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $81.56 | 2023-2025 | Valtoco |
| Ucb, INC. | $80.59 | 2023-2025 | Briviact, Nayzilam |
| Neos Therapeutics, LP | $69.17 | 2024-2025 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $35.57 | 2019-2021 | |
| Adlon Therapeutics L.P. | $33.04 | 2021 | |
| Haemonetics Corporation | $30.77 | 2023 | Teg6s Hemostasis System |
| Ironshore Pharmaceuticals INC. | $23.94 | 2024 | |
| Idorsia Pharmaceuticals US INC | $19.78 | 2023 | Quviviq |
| Amgen INC. | $19.60 | 2024 | Uplizna |
| Janssen Pharmaceuticals, INC | $19.04 | 2023 | Spravato |
| Itamar Medical INC | $16.88 | 2025 | Watchpatone |
| Corium, LLC | $14.56 | 2023 | Azstarys |
| Eisai INC. | $14.17 | 2024 | |
| Tris Pharma INC | $13.92 | 2024 | Dyanavel Xr |
| Almatica Pharma LLC | $13.26 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendir Soorya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.